<DOC>
	<DOC>NCT02063113</DOC>
	<brief_summary>The aim of this study is to determine whether the presence of vulnerability detected by geriatricians is associated with treatment discontinuation in older patient. During the comprehensive geriatric assessment realized before the decision-treatment, the following data are recorded and their impact in the therapeutic changes will also be analysed: comorbidity, age, depression, functional status, the cognitive impairment and malnutrition.</brief_summary>
	<brief_title>Vulnerability and Therapeutic Changes in Older Patients With Multiple Myeloma.</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms, Plasma Cell</mesh_term>
	<criteria>Patients aged 70 years and older Patients referred for a assessment of a newly diagnosed multiple myeloma Patients for who the initial therapy proposed is either melphalanprednisonethalidomide or melphalanprednisonebortezomib or included in a phase 3 trial. Patients who provide informed written consent Patients who refuse the study Patients who won't have therapy Patients can't respond to geriatric assessment because of severe cognitive disorder Patients with a legal guardian</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Multiple myeloma,</keyword>
	<keyword>Older patient,</keyword>
	<keyword>Treatment,</keyword>
	<keyword>Geriatric assessment</keyword>
</DOC>